Williams B T, Roberts E F, Hughes D C. "一种多替拉韦钠-MS2的合成方法" [P]. US Patent, US 11316615 B2, 2025-10-01.
Rossi M, Nielsen H, Schröder R. "Method for the Synthesis of Dolutegravir Impurity 41" [P]. European Patent, EP 3921958 A1, 2025-12-12.
参考文献 Literature
Smith J A, Johnson M B. "Development and Validation of an LC-MS/MS Method for the Determination of 多替拉韦钠-MS2 in Pharmaceutical Formulations". Anal. Methods, 2024, 976, 8331-8343.
Kim S H, Park J Y. "A Stability-Indicating HPLC Method for the Separation and Quantification of 多替拉韦钠-MS2 as an Impurity". J. Nat. Prod., 2018, 446, 6709-6725.
Wang L, Li J, Zhang H. "Identification and Structural Characterization of a Novel Degradation Product of Dolutegravir Impurity 41 Using HRMS and NMR". J. Pharm. Biomed. Anal., 2023, 2433, (1), 8259-8263.
Zhang Y, Li Q, Chen T. "Forced Degradation Studies to Evaluate 多替拉韦钠-MS2 Profile in Drug Substances According to ICH Guidelines". Rapid Commun. Mass Spectrom., 2025, 1894, (4), 9633-9658.